APA
DeAngelo D. J., Stock W., Stein A. S., Shustov A., Liedtke M., Schiffer C. A., Vandendries E., Liau K., Ananthakrishnan R., Boni J., Laird A. D., Fostvedt L., Kantarjian H. M. & Advani A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. : Blood advances.
Chicago
DeAngelo Daniel J, Stock Wendy, Stein Anthony S, Shustov Andrei, Liedtke Michaela, Schiffer Charles A, Vandendries Erik, Liau Katherine, Ananthakrishnan Revathi, Boni Joseph, Laird A Douglas, Fostvedt Luke, Kantarjian Hagop M and Advani Anjali S. 2017. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. : Blood advances.
Harvard
DeAngelo D. J., Stock W., Stein A. S., Shustov A., Liedtke M., Schiffer C. A., Vandendries E., Liau K., Ananthakrishnan R., Boni J., Laird A. D., Fostvedt L., Kantarjian H. M. and Advani A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. : Blood advances.
MLA
DeAngelo Daniel J, Stock Wendy, Stein Anthony S, Shustov Andrei, Liedtke Michaela, Schiffer Charles A, Vandendries Erik, Liau Katherine, Ananthakrishnan Revathi, Boni Joseph, Laird A Douglas, Fostvedt Luke, Kantarjian Hagop M and Advani Anjali S. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. : Blood advances. 2017.